Levodopa (L-dopa)-induced motor complications, including motor fluctuations and dyskinesia, affect almost all patients with Parkinson’s disease (PD) at some point during the disease course, with relevant implications in global health status. Various dopaminergic and nondopaminergic pharmacological approaches as well as more invasive strategies including devices and functional surgery are available to manage such complications…
Articles Collection
- This article collection was made possible by Cynapsus.
Footer
Copyright © 1999-2024 John Wiley & Sons, Inc. All Rights Reserved.
